Common Cold Clinical Trial
Official title:
Effects of a Common Cold Treatment on Cognitive Function
A reduction in alertness and lower levels of performance are commonly associated with the common cold. Paracetamol has been shown to be more effective than placebo in treating symptoms associated with upper respiratory tract infection; caffeine has been shown to increase levels of alertness and improve performance of people suffering from colds. This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering from the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.
Status | Completed |
Enrollment | 72 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Present with symptoms of the common cold of no more than 96 hours duration - Score of "2" or more on a self-rating for malaise and at least 4 other cold symptoms Exclusion Criteria: - Pregnancy or lactation - Hypersensitivity to drugs - Have taken caffeine in the last 12 hours or treated their cold |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Common Cold Centre | Cardiff | Wales |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test | The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated. | Baseline to 30 minutes post treatment administration | No |
Secondary | Adjusted Mean Change From Baseline in Number of Valid Responses to RVIP Cognitive Test | The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated. | Baseline to 60 minutes post treatment administration | No |
Secondary | Adjusted Mean Change in Baseline in Valid Reaction Time to RVIP Cognitive Test | The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. Mean valid reaction time was determined. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Mean Change From Baseline in Number of Incorrect and Missed Responses to RVIP Cognitive Test | The RVIP assessed the performance of visual attention mechanisms in remaining vigilant to periodically occurring events. Participants monitored a series of single numbers (0-9) appearing in the centre of the screen. During the RVIP task, participants responded to consecutive sequences of three odd or three even numbers by pressing the corresponding response button as quickly and accurately as possible. The test lasted approximately 9 minutes and mean number of valid responses to stimulus was calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Adjusted Mean Change From Baseline in Number of Valid Responses to Sustained Attention Tasks (SAT) Cognitive Test | Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Mean Change From Baseline in Number of Incorrect and Missed Responses to SAT Cognitive Test | Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Adjusted Mean Change From Baseline in Valid Reaction Time to SAT Cognitive Test | Auditory and visual attention of participants was evaluated using a validated Sustained Attention task. For the sustained visual attention task, participants were required to respond to the letter 's' every time it appears in a continuous stream of letters presented on a screen. For the sustained auditory attention task, participants responded to the number '8' every time it appears in a continuous stream of numbers presented through headphones. Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Adjusted Mean Change From Baseline in Number of Valid Responses to Divided Attention Task (DAT) Cognitive Test | For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid responses to visual and auditory tests were calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Adjusted Mean Change From Baseline in Valid Reaction Time to DAT Cognitive Test | For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of valid reaction time to visual and auditory tests were calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Mean Change From Baseline in Number of Incorrect and Missed Responses to DAT Cognitive Test | For the DAT Cognitive test, auditory and visual stimuli were simultaneously presented and participants were asked to respond to occurrences of 's' (visual) or '8' (auditory). Total test duration was approximately 6 minutes. Mean values of incorrect and missed responses to visual and auditory tests were calculated. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Secondary | Adjusted Mean Change From Baseline in Mood Alertness and Physical Sensation Scales (MAPSS) Cognitive Test | Mood patterns was evaluated using the Mood, Alertness and Physical Sensation Scales (MAPSS) which comprised of 23 questions describing moods and physical sensations, on a 9-point scale anchored at the left hand end with 'not at all' and the right hand end with 'extremely'. For each question, '9' represented the 'best' score and '1' represented the 'worst' score. Mean score was calculated by summing the responses and dividing by the number of questions answered. MAPSS Questionnaire was further divided into three main clusters: Alertness; Anxiety and Headache as per the questions. | Baseline, 30 minutes and up to 60 minutes post treatment administration | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT02451163 -
DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly
|
Phase 2 | |
Completed |
NCT01944631 -
Iota-Carrageenan Nasal Spray in Common Cold
|
Phase 4 | |
Completed |
NCT01651715 -
Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections
|
Phase 1/Phase 2 | |
Completed |
NCT00963443 -
Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold
|
Phase 3 | |
Completed |
NCT00778648 -
Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
|
N/A | |
Completed |
NCT00065715 -
Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)
|
Phase 3 | |
Completed |
NCT00032500 -
Evaluation of Echinacea for the Common Cold
|
Phase 2 | |
Not yet recruiting |
NCT05070650 -
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
|
Phase 3 | |
Completed |
NCT04144491 -
Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda
|
N/A | |
Not yet recruiting |
NCT04073511 -
Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold
|
N/A | |
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01277081 -
Effect of Paracetamol on the Common Cold
|
Phase 2 | |
Completed |
NCT01728090 -
Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections
|
Phase 4 | |
Completed |
NCT00405509 -
The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
|
N/A | |
Completed |
NCT01033526 -
Symptomatic Treatment of Common Cold Symptoms
|
Phase 4 | |
Completed |
NCT05556148 -
Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
|
Phase 4 | |
Terminated |
NCT03339726 -
Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold
|
Phase 2 | |
Completed |
NCT01361399 -
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
|
Phase 3 |